BRIEF—Anocca raises $36 million in equity financing

Privately-held Swedish company Anocca has raised around $36 million through an equity financing round led by AMF and Mellby Gård.

The company uses in-house analytical methods to identify and produce T-cells.

The money will be used to further develop Anocca's process, which is designed to enable the discovery and manufacture of next generation cell therapies for cancer on an industrial scale.

Anocca also plans to progress its first candidates into clinical trials.

Chief executive Reagan Jarvis said: "In recent years, we have made great progress in automating our research platform,” adding the start of clinical trials is “planned to be initiated in 2024.”